Ark. accuses AstraZeneca of off-label marketing; Europeans want ban on pharma repackaging;

> Arkansas is suing AstraZeneca, claiming that the drugmaker pushed its antipsychotic Seroquel for off-label uses, harming patients and costing the state millions. Report

> To fight counterfeiting, European pharma companies are calling for a ban on repackaging of medicines. Report

> Pfizer was named one of the 50 friendliest companies to the environment in the U.K. by the Sunday Times, cited for its energy-reduction programs, its increased recycling, and its cutback in chemicals use. Report

> SkyePharma's chief executive Frank Condella is heading for the exit as the drug-delivery company wraps up a restructuring; COO Ken Cunningham will take the reins. Report

> Pfizer is planning to cut 500 more jobs in France by 2011, according to trade union sources; already the drugmaker has eliminated 400 jobs there as part of its company-wide restructuring. Report

> Schering-Plough named Tessa Hilado vice president and treasurer for global finance, reporting to EVP and CFO Robert Bertolini. Report

> India's Ranbaxy Laboratories has launched new operations in Yemen, via a deal with local company Natco. Report

> Saying it had the wrong patient population, Merck has discontinued its ACHIEVE imaging study for its cholesterol drug MK-0524A. Merck report

> Daiichi Sankyo is buying Germany's U3 Pharma for $235 million in cash. Report

> Regeneron and Sanofi-Aventis announced that their experimental therapy aflibercept missed a mid-stage goal for an ovarian cancer trial. Report

> In a first, researchers have developed a primate model for Huntington's disease, eliciting harsh criticism from animal rights experts even as it paves the way for future primate models for a host of degenerative brain disorders. Report

And Finally... One of Senator Kennedy's best chances in defeating the malignant brain tumor that afflicts him could be an experimental vaccine, and reports are already circulating that he may be included in a trial. Vaccine report

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.